Core Viewpoint - The market experienced a decline primarily due to disappointing earnings from JPMorgan Chase and concerns over potential credit card interest rate caps, impacting the financial sector significantly [1][2]. Group 1: Market Performance - The Dow Jones Industrial Average fell by 398.21 points, a decrease of 0.8030% [1]. - JPMorgan Chase's shares dropped by 3.79% following weaker-than-expected profit and revenue results, which included a $2.2 billion impact from its Apple Card partnership [2]. - Other notable declines included Salesforce at -6.98%, Visa at -3.99%, and IBM at -2.81% [2]. Group 2: Advancers in the Market - Despite the overall downturn, Walmart increased by 1.93%, Boeing by 1.89%, and Johnson & Johnson by 1.87% [3]. - Cisco Systems saw a gain of 1.77%, while Home Depot advanced by 1.22% [3]. Group 3: Economic Indicators - The Bureau of Labor Statistics reported that inflation remained steady in December 2025, with core inflation marking its lowest annual increase since early 2021 [3].

The fresh capital will be used to expand its offline retail footprint, strengthen brand-led marketing, expand rapidly across quick commerce and marketplacesIn addition to the capital infusion, OrbiMed’s Dr Sunny Sharma and Sumona Chakraborty will join Pee Safe’s boardPee Safe has secured $32 Mn (about INR 288 Cr) in its Series C round from Netmeds-backer OrbiMed in a mix of primary and secondary share sale Femtech startup Pee Safe has secured $32 Mn (about INR 288 Cr) in its Series C round from Netmeds-bac ...

Summary of ORIC Pharmaceuticals FY Conference Call Company Overview - **Company Name**: ORIC Pharmaceuticals (NasdaqGS:ORIC) - **Industry**: Oncology - **Mission**: Overcoming Resistance in Cancer, focusing on developing therapies for cancer patients [2][3] Key Pipeline Assets - **Rinsey-Metastat**: A PRC2 inhibitor for prostate cancer, expected to have a phase three data readout in the second half of 2027 [3][11] - **Enosertinib**: A brain-penetrant TKI for lung cancer, targeting EGFR exon 20 and PAC mutations, with a phase three dose selected [5][35] Financial Position - **Cash Runway**: Well-funded with cash runway extending into the second half of 2028, allowing for continued development of both pipeline assets [3][11] Clinical Development Highlights Rinsey-Metastat - **Combination Studies**: Being developed in combination with apalutamide (J&J) and daralutamide (Bayer) [4][7] - **Safety Profile**: Demonstrated a differentiated safety profile compared to competitors, which is crucial for long-term dosing [8][29] - **Efficacy Data**: - Confirmed PSA response rates of 40% for PSA 50 and 20% for PSA 90, significantly higher than expected rates for AR inhibitors alone [24] - ctDNA clearance rate of 59%, indicating strong activity [26][27] Enosertinib - **CNS Activity**: Achieved a 100% intracranial objective response rate (ORR) in patients with measurable disease, highlighting its potential in treating CNS metastases [10][33] - **Patient Enrollment**: Allowed patients with active untreated CNS metastases, which is uncommon in competitor studies [34] Competitive Landscape - **Main Competitor**: Pfizer's mevrometostat, which has shown promising results but comes with higher toxicity [6][28] - **Market Opportunity**: The prostate cancer market is substantial, with AR inhibitors generating $11 billion in global revenue [16][17] Future Milestones - **Phase 3 Studies**: Expected to initiate one or two phase 3 studies within the year for both Rinsey-Metastat and Enosertinib [46] - **Data Releases**: Anticipated data from dose optimization studies in Q1 2026, focusing on efficacy and safety [50] Additional Insights - **Long-term Durability**: The combination of Rinsey-Metastat with AR inhibitors aims to extend the durability of treatment, addressing a significant unmet need in prostate cancer [17][19] - **Broader Applications**: Potential future development of PRC2 inhibitors in other cancers, including lung and breast cancer [30] Conclusion - ORIC Pharmaceuticals is positioned to make significant advancements in oncology with its innovative pipeline, particularly in addressing unmet needs in prostate and lung cancer, while maintaining a strong financial position to support its development efforts [46]

CEO Joaquin Duato presented a strong outlook for Johnson & Johnson's (J&J) revenue growth in 2026, with particular optimism about oncology. Duato identified six major growth drivers, three in pharma (oncology, immunology, and neuroscience) and three in medtech (surgery, cardiovascular, and vision). These drivers position J&J to reach 5-7% annual growth and even exceeding that by the end of the decade, with potential to reach double digit growth in the 2030s. Oncology is set to play a major role in J&J’s op ...

Mar Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities experienced a strong momentum in 2025 and marked their second consecutive year of double-digit gains. The market witnessed one of the fastest recoveries following its dip into bear territory in April. Market leadership continued to narrow as Mega-cap stocks and AI-driven companies dominated the lands ...

Core Insights - Johnson & Johnson's (JNJ) MedTech segment accounts for approximately 36% of total revenues and focuses on high-growth markets, particularly in cardiovascular interventions [2][3] MedTech Segment Performance - Sales in the MedTech business have improved over the past two quarters, driven by acquisitions of Abiomed and Shockwave, as well as growth in Surgical Vision and wound closure [4] - The MedTech segment is expected to maintain strong momentum in Cardiovascular, Surgery, and Vision, supported by the adoption of newly launched products [4] Challenges and Strategic Moves - J&J faces challenges in the Chinese market due to the volume-based procurement (VBP) program, which is impacting sales [5] - The company plans to separate its Orthopaedics franchise into a standalone company, DePuy Synthes, to enhance growth and margins [6] Future Outlook - J&J anticipates better growth in the MedTech business by 2026, driven by new product launches and a focus on high-growth markets [7] - The company expects a compound annual growth rate (CAGR) of around 5.4% for the MedTech unit over the next three years [8] Competitive Landscape - J&J's MedTech unit competes with major players like Medtronic, Abbott, Stryker, and Boston Scientific, each specializing in various medical device sectors [9][10] Financial Performance - J&J's shares have outperformed the industry, rising 44.9% over the past year compared to a 21.9% increase in the industry [12] - The company's shares are currently trading at a price/earnings ratio of 18.22, higher than the industry average of 17.56 [14] Earnings Estimates - The Zacks Consensus Estimate for J&J's 2026 earnings has slightly increased from $11.47 to $11.48 over the past 30 days [15]

Core Insights - Johnson & Johnson is presenting 11 abstracts at the 64th Annual Meeting of the American College of Neuropsychopharmacology, focusing on advancements in neuropsychiatry, particularly in major depressive disorder (MDD) and treatment-resistant depression (TRD) [1][2] Group 1: Research Presentations - Key presentations include analyses of CAPLYTA (lumateperone) for remission in MDD, metabolic profiles of seltorexant versus quetiapine XR in MDD with insomnia, and effects of SPRAVATO (esketamine) on anhedonia in TRD [3][4] - Specific posters will cover the efficacy of lumateperone in various demographic and clinical subgroups, as well as treatment-emergent adverse events in MDD patients [3][4] Group 2: Company Commitment - Johnson & Johnson emphasizes its commitment to addressing unmet needs in depression, schizophrenia, and bipolar disorder, aiming for disease remission through innovative research and clinical findings [2] - The company is advancing its portfolio with a focus on novel mechanisms and AI-driven precision tools to redefine standards of care in neuropsychiatry [2] Group 3: Major Depressive Disorder (MDD) Insights - MDD affects approximately 332 million people globally, representing about 4% of the population, with around 22 million adults in the U.S. experiencing at least one major depressive episode in 2023 [6] - The disorder is complex and heterogeneous, with responses to treatment varying widely, highlighting the need for personalized approaches [6][7] - Approximately 60% of MDD patients experience insomnia symptoms, which significantly impact their quality of life and increase the risk of depressive relapse [7] Group 4: Treatment-Resistant Depression (TRD) Insights - About one-third of adults with MDD are classified as having TRD, defined as inadequate response to two or more oral antidepressants [8] - TRD poses a significant economic burden and affects patients' lives severely, with a high percentage not achieving remission even after multiple treatment attempts [8]

Investment Rating - The report maintains a positive outlook on the development of dual and triple antibodies in multiple myeloma (MM) and recommends monitoring the progress of TCE monotherapy and combination therapies in MM, including the EMD population [1][15]. Core Insights - The 67th ASH Annual Meeting highlighted significant advancements in hematology, particularly in the treatment of multiple myeloma, diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [31]. - In multiple myeloma, the Tec-Dara combination therapy demonstrated a 36-month overall survival (OS) rate of 83.3%, significantly higher than the 65.0% in the control group, with a hazard ratio (HR) of 0.46 [32]. - The MSD ROR1 ADC showed promising first-line potential in DLBCL, with 24-month OS and progression-free survival (PFS) rates of 94% and 84%, respectively, outperforming existing treatments [33]. - Eli Lilly's Pirto showed improved PFS and OS trends compared to BR, but the executive admitted it may not become the first-line choice for CLL/SLL due to limited follow-up data and current treatment practices favoring covalent BTK inhibitors [34]. Summary by Sections 1. R/R MM: Focus on Dual/Triple Antibodies and TCE Therapies - Johnson & Johnson's BCMA/CD3+daratumumab therapy received FDA's "National Priority Voucher," reducing review time to 1-2 months, showing excellent efficacy in high-risk patients [7][15]. - IBI3003 from Innovent demonstrated an overall response rate (ORR) of 83.3% in high-risk patients, with a 100% minimal residual disease (MRD) negative rate in those achieving complete response (CR) [16]. - AstraZeneca's AZD0120 (BCMA/CD19 CAR-T) is projected to exceed $5 billion in sales, with a 100% ORR in treated patients [20][21]. 2. DLBCL: MSD ROR1 ADC Shows First-Line Potential - The MSD ROR1 ADC demonstrated a 24-month OS rate of 94% and a PFS rate of 84%, outperforming R-CHOP and Pola-CHP treatments [22][23]. - In high-risk populations, the ORR was 75% for patients with extramedullary disease (EMD), with a 100% ORR in the 1200 µg/kg dose group [23]. 3. CLL/SLL: Pirto May Not Become First-Line Choice - Pirto vs BR showed a 24-month PFS of 93.4% vs 70.7%, but the data is still immature, with a median follow-up of 28 months [25][27]. - The safety profile of Pirto indicated a 40% incidence of grade 3 or higher treatment-emergent adverse events (TEAEs), compared to 67.4% for BR [25][27].

Johnson & Johnson (JNJ) closed the most recent trading day at $209.72, moving +2.61% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.16%. On the other hand, the Dow registered a gain of 0.17%, and the technology-centric Nasdaq increased by 0.26%. Prior to today's trading, shares of the world's biggest maker of health care products had lost 3.4% lagged the Medical sector's gain of 2.84% and the S&P 500's gain of 1.89%.The upcoming earnings release of Johnson & Johnson will ...

Johnson & Johnson convinced Delaware's highest court to throw out part of a $1 billion damages award for breaching its 2019 agreement to buy Auris Health, a maker of surgical robots. ...